

# Etoricoxib

Catalog No: tcsc1047



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

202409-33-4

**Formula:**

$C_{18}H_{15}ClN_2O_2S$

**Pathway:**

Immunology/Inflammation

**Target:**

COX

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 100 mg/mL (278.68 mM; Need ultrasonic)

**Alternative Names:**

MK-0663;L-791456

**Observed Molecular Weight:**

358.84


## Product Description

Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active **COX-2** inhibitor, with **IC<sub>50</sub>**s of 1.1  $\mu$ M and 116  $\mu$ M for COX-2 and COX-1 in human whole blood.

IC50 & Target: IC50: 1.1  $\mu$ M (COX-2, in human whole blood), 116  $\mu$ M (COX-1, in human whole blood)<sup>[1]</sup>

**In Vitro:** Etoricoxib (MK-0663) is a selective and orally active COX-2 inhibitor, with IC<sub>50</sub>s of 1.1  $\mu$ M, 116  $\mu$ M and 5  $\mu$ M for COX-2, COX-1 in human whole blood and purified human COX-2, respectively. Etoricoxib (MK-0663) shows inhibitory effect on PGE2 production by CHO (COX-2) cells (IC<sub>50</sub>, 79 nM), on purified human COX-2 with detergent (IC<sub>50</sub>, 4.1  $\mu$ M), and on purified PGE2 production by U937 microsomes (low substrate; IC<sub>50</sub>, 12.1  $\mu$ M). However, Etoricoxib (MK-0663) has little activity against COX-1 with a K<sub>i</sub> of 167  $\mu$ M<sup>[1]</sup>.

**In Vivo:** Etoricoxib (MK-0663) (0.1-30 mg/kg, p.o.) dose-dependently inhibits carrageenan-induced paw edema, carrageenan-induced paw hyperalgesia, and endotoxin-induced pyresis in rats. Etoricoxib ( $\geq 10$  mg/kg) completely reverses hyperalgesia response in the rat hyperalgesia model. Etoricoxib (MK-0663) (200 mg/kg/day) has no effect on urinary <sup>51</sup>Cr excretion in rats, and nor in monkeys at 100 mg/kg/day<sup>[1]</sup>. Etoricoxib (MK-0663) (50 and 100 mg/kg) potently increases the malondialdehyde (MDA) and myeloperoxidase (MPO) levels, and decreases the total glutathione (tGSH) and glutathione reductase (GSHRd) levels in rats. Etoricoxib (MK-0663) (100 mg/kg) significantly inhibits the decrease of NO in rats<sup>[2]</sup>. Etoricoxib (MK-0663) (0.64 mg/kg, p.o.) reduces the features such as multiple plaque lesions, hyperplasia and dysplasia induced by 1,2-dimethylhydrazine dihydrochloride (DMH) in rats<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!